Comprehensive evaluation of PD-1 inhibitors marketed in China based on a Quick Guideline for drug evaluation and selection in Chinese Medical Institutions (second edition)

Abstract

Objective: To conduct a comprehensive evaluation of PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China, using A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition), and to provide a reference for the selection of and decision-making on clinical drugs in hospitals.

Method: The Sanzhi drug evaluation and selection system was used to evaluate the PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China, according to five characteristics: pharmaceutical characteristics, efficiency, safety, economy, and others.

Results: Based on the above evaluation criteria, the scores of all PD-1 inhibitors were above 61 points. The main difference among the five characteristics were efficiency and economy. The difference between the other characteristics was relatively small. Sintilimab injection had the highest score due to the advantages among characteristics except the other attributes. Nivolumab injection (100 mg/10 mL (10 mg/mL)) had the lowest total score due to its low effectiveness and economy scores.

Conclusion: PD-1 inhibitors are effective therapeutic drugs for immunotherapy in patients with advanced non-small cell lung cancer. Different PD-1 inhibitors have different advantages in clinical treatment. The comprehensive evaluation of PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China through A Quick Guide for Drug Evaluation and Selection of Chinese Medical Institutions (Second Edition) can provide a basis for drug selection and scientific, reasonable, and safe drug use in medical institutions.

Keywords

PD-1 inhibitors / Advanced non-small cell lung cancer / Drug evaluation

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. May-Jun 2024;74(3):229–263.

[2] Toi Y, Sugawara S, Kawashima Y, et al. Association of immune-related adverse Events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncol. Nov 2018;23(11):1358–1365.

[3] Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. Feb 21 2023;22(1):40.

[4] Dehghani T, Shahrjerdi A, Kahrizi MS, et al. Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC);the recent advances. Pathol Res Pract. Jun 2023;246:154470.

[5] Zuo H, Wan Y. Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis. Cancer Gene Ther. Oct 2022;29(10):1342–1354.

[6] Nakamura T, Sato T, Endo R, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer. Jul 2021;9(7).

[7] Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H, Hashemy SI. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. Int Immunopharmacol. Sep 2021;98:107870.

[8] Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.

[9] Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. Feb 20 2022;40(6):586–597.

[10] Zhigang Z, Zhanjun D, Jianping L. A Quick guideline for drug evaluation and selection in Chinese medical institutions (Second edition). Herald of Medicine. 2023;42(4):447–456. https://doi.org/10.3870/j.issn.1004-0781.2023.04.001.

[11] Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. Jan 21 2022;21(1):28.

[12] Liu L, Huang X, Shi F, et al. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res. Feb 9 2022;41(1):56.

[13] Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. Mar 12 2022;15(1):24.

[14] Katsuya H, Suzumiya J, Kimura S. Clinical PD-1/PD-L1 blockades in combination therapies for lymphomas. Cancers. Nov 14 2023;15(22).

[15] CSCO. Chinese Society of Clinical Oncology (CSCO). Guideline for the Diagnosis and Treatment of Non-small Lung Cancer. Bijing People’s Medical Publishing House.;2024;2024.

[16] NCCN. NCCN clinical practice guidelines in OncologyNon-small cell lung cancer. National Comprehensive Cancer Network;2024, 2024.04.23 https://www.nccn.org/p rofessionals/physician_gls/pdf/nscl.pdf. Version 5.

[17] NHC. Guidelines for the diagnosis and treatment of primary lung cancer (2022 edition). Medical Journal of Peking Union Medical College Hospital. 2022;13(4):549–570. https://doi.org/10.12290/xhyxzz.2022-0352.

[18] Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237.

[19] Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–376.

[20] Brustugun OT, Sprauten M, Helland Å. Real-world data on nivolumab treatment of non-small cell lung cancer. Acta Oncol. Mar 2017;56(3):438–440.

[21] Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. Sep 2019;135:188–195.

[22] Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. Oct 2020;15(10):1636–1646.

[23] Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. May 1 2021;7(5):709–717.

[24] Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial. J Thorac Oncol. May 2023;18(5):628–639.

[25] Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. May 2024;12(5):355–365.

[26] Ren S, Chen J, Xu X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol. Apr 2022;17(4):544–557.

[27] Khunger M, Jain P, Rakshit S, et al. Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. May 2018;19(3): e335–e348.

[28] Zeng T, Qin Q, Bian Z, Li J. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artif Cells, Nanomed Biotechnol. Dec 2019;47(1):4194–4201.

[29] Passiglia F, Galvano A, Rizzo S, et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. Mar 15 2018;142(6):1277–1284.

[30] Zhou GW, Xiong Y, Chen S, Xia F, Li Q, Hu J. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: a meta-analysis of randomized clinical trials. Medicine (Baltim). Aug 2016;95(35):e4611.

[31] Zhang L, Qian Y, Li J, et al. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future Oncol. May 2022;18(15):1896–1905.

[32] Guo Y, Jia J, Hao Z, Yang J. Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials. Front Pharmacol. 2023;14:1172969.

[33] Zheng Y, Feng B, Chen J, You L. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1273220.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.